The activation of AKT signaling, a well-known activated pathway involved in cancers, is involved in the induction of chemokine transcription in response to SARS-CoV-2 infection in a preclinical model, and treatment with the AKT inhibitor GSK690693 markedly reduced CXCL9, CXCL10 and CXCL11 gene expression [41]. The gene discussed is CXCL9; the disease is cancer.